Nausea and vomiting as side effects are among the most common ones associated with cancer chemotherapy. They are often referred to as chemotherapy induced nausea and vomiting (CINV), the incidence of which increases in response to the increasing incidence of cancer. CINV is significantly experienced by patients who undergo chemotherapy. There are two major classifications of CINV, vis-à-vis, delayed CINV, which occurs between a day and five days after chemotherapy, and CINV, which occurs within 24 hours of the treatment. Currently, drugs such as Zofran generic (ondansetron), Emend (aprepitant), Aloxi (palonosetron), Kytril generic (granisetron), and Akynzeo (netupitant-palonosetron FDC) are available in the market for the treatment of the condition. However, in the forthcoming years the global CINV market is likely to gain from the approval of two new drugs namely, Rolapitant and SUSTOL.
Get Sample Report:
Q: What factors are at fore of boosting the global CINV existing and pipeline drugs market?
A: Due to the continuous rise in the incidence of cancer, the world is witnessing an increasing number of patients undergoing chemotherapy. According to the online database for cancer GLOBOCAN, which is owned and managed by the International Agency for Research on Cancer (IARC), over 14.1 million people around the world were diagnosed with cancer in 2012, as compared to 12.7 million in 2008. This number however excludes those affected by the non-melanoma skin cancer. Furthermore, the study projects the incidence of cancer to reach 17.1 million by the end of 2020. These facts are indicative of the growing incidence of various cancer types, which might compel oncologists to prescribe chemotherapy. As per studies, 25% to 30% of cancer patients undergo chemotherapy. Of these patients 70% to 80% exhibit vomiting and nausea symptoms, which require appropriate CINV treatment. Hence over the next few years, the demand for CINV drugs is expected to increase thus boosting the global CINV market.
Q: How will the market gain from the launch of novel drugs?
A: To counter the increasing incidence of cancer, research institutes and healthcare organizations are focusing on novel therapeutics. The approval of new drugs such as SUSTOL (APF-530) and rolapitant therefore creates considerable scope for the global CINV existing and pipeline drugs market exhibit a higher CAGR in the forthcoming years. During clinical studies, these drugs in pipeline have shown better efficacy than those available in the market already. Therefore the impending launch of these potentially more efficacious drugs is likely to encourage physicians in prescribing them over their counterparts. While the CINV existing and pipeline drugs market foresee lucrative prospects in the launch of novel drugs, the looming patient expiry of Aloxi and Emend pose threat.